glp-1 and liver disease toxicity The future of incretins in the treatment of obesity non-alcoholic fatty liver Glucagon-like peptide (GLP)-1 and GLP-2

Recuerda que el uso de un complemento alimenticio no sustituye una dieta variada y equilibrada

doi: 10.3389/fcvm.2025.1535134 Received 26 November 2024 Accepted 28 March 2025 Published 24 April 2025 Volume 12 - 2025 Edited by Preetha Shridas, University of Kentucky, United States Reviewed by Aneesh Dhore-patil, Houston Methodist Hospital, United States Raffaele Carraro, La Princesa University Hospital, Spain Updates Copyright 2025 Turkistani

PMC 2792575

2009;32:158990 England MR, Hartnell JM, Wsp HJM

[*] cAMP Production: One key intracellular messenger activated by Sermorelin is cyclic adenosine monophosphate (cAMP)

10.1016/j.sjbs.2018.07.013 28 BaldiA.AbramoviH.Poklar UlrihN.DagliaM